BioStem Technologies, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 0JQ.F | CLGN | CELU | MDXG | SVA.TO | CELZ | |
|---|---|---|---|---|---|---|
| Market cap | 18.97M | 12.18M | 26.25M | 466.96M | 39.65M | 4.95M |
| P/E (TTM) | 1.3 | — | — | — | 10.5 | — |
| Forward P/E | — | -10.8 | -1.4 | 30.0 | -3.5 | -0.7 |
| Price/book | 0.7 | 2.1 | -0.7 | 2.2 | -1.7 | 0.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −65.78% | −80.60% | −52.13% | −56.34% | −26.67% | −78.05% |
| Today | −2.12% | +2.92% | −1.02% | −1.54% | −8.70% | −3.21% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All 0JQ.F news ›[EFFECT] BioStem Technologies, Inc. SEC Filing
BioStem Technologies, Inc. SEC Filing (Oct 13, 2026) Stock Titan [EFFECT] BioStem Technologies, Inc. SEC Filing Sentiment and the balance of points Rhea-AI Sentiment reads the wording of the document, how positive or negative its language…
BioStem Technologies Completes $3 Million Private Placement Financing
BioStem Technologies ( (BSEM) ) has provided an update. The most recent analyst rating on (BSEM) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on BioStem Technologies stock, see the BSEM Stock Forecast…
BioStem Technologies sells $3M in equity offering
The offering’s first sale date was September 29, 2026, and it was reported under Rule 506(b). BioStem Technologies, Inc. reported $3,000,000 USD sold and $0 USD remaining to be sold in an offering of equity and options, warrants or other…
BioStem Technologies CEO exercises 250K share options
BioStem Technologies (OTC: BSEM) develops and manufactures placental-derived allografts for advanced wound care and regenerative therapies using its BioRetain® process. - [Form 4] BioStem Technologies, Inc. Insider Trading Activity BioStem…
BioStem Technologies’ CEO and COO invest $1M in cash through exercise of stock options
BioStem (BSEM) CEO & COO exercised options to buy 500,000 shares at $2.00. BioStem Technologies (BSEM) on Thursday announced its Chair and CEO, Jason Matuszewski, and COO, Andrew Van Vurst, each exercised a portion of their outstanding…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- stocktitan.net3
- globenewswire.com1
- seekingalpha.com1
- theglobeandmail.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 6 articles, not a forecast.